SCHEMBL1001567

SCHEMBL1001567

CC(C)c1ccc(NC(=O)c2cncc(S(=O)(=O)c3ccccc3)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
TP53 P04637 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
PRMT1 Q99873 3/20 0.52
NAMPT P43490 4/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 2/20 0.52
LMNA P02545 2/20 0.52
MAPK1 P28482 1/20 0.52
CYP2C9 P11712 2/20 0.50
CYP3A4 P08684 1/20 0.50
USP36 Q9P275 1/20 0.49
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1002051 0.85 SMN1; SMN2 (0.62) NPC1RAB9ATP53SMN1; SMN2KMT2A
SCHEMBL28817678 0.82 NPC1 (0.68) NPC1RAB9ATP53SMN1; SMN2KMT2A
SCHEMBL1003301 0.78 RAB9A (0.58) NPC1RAB9ATP53SMN1; SMN2KMT2A
SCHEMBL1001482 0.77 MAPT (0.60) NPC1RAB9ATP53SMN1; SMN2KMT2A
SCHEMBL1000727 0.76 MEN1 (0.70) NPC1RAB9ATP53SMN1; SMN2KMT2A
SCHEMBL1002025 0.75 MEN1 (0.66) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL2563194 0.75 NPC1 (0.68) NPC1RAB9ATP53SMN1; SMN2KMT2A
SCHEMBL27837892 0.74 LMNA (0.65) NPC1RAB9ATP53SMN1; SMN2KMT2A
SCHEMBL1001170 0.74 SMN1; SMN2 (0.64) NPC1RAB9ATP53SMN1; SMN2KMT2A
SCHEMBL1002215 0.74 SMN1; SMN2 (0.54) NPC1RAB9ATP53SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104352492-B Extend enzyme inhibitor using arylsulfonyl derivatives as the long chain fatty acids of active ingredient MSD K.K.公司 2017-12-05 CN disclosed
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
CN-102015638-A Long-chain fatty acid elongase inhibitor containing arylsulfonyl derivative as active ingredient BANYU PHARMA CO LTD 2011-04-13 CN disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 NPC1 899/4885RAB9A 3688/4885TP53 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.